EGFR and cancer: Monoclonal antibodies and vaccines targeting this pathway have been implemented clinically, including the monoclonal antibodies cetuximab, panitumumab and nimotuzumab; the small tyrosine kinase molecules erlotinib and gefitinib; the EGF-based cancer vaccine CIMAvax®; and a EGFR-based HER-1 cancer vaccine.